- Home
- WINT vs NDRA Comparison
WINT vs NDRA Comparison
Compare WINT & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- NDRA
- Stock Information
- Founded
- WINT 1992
- NDRA 2007
- Country
- WINT United States
- NDRA United States
- Employees
- WINT N/A
- NDRA N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- WINT Health Care
- NDRA Health Care
- Exchange
- WINT Nasdaq
- NDRA Nasdaq
- Market Cap
- WINT 2.2M
- NDRA 2.3M
- IPO Year
- WINT 1995
- NDRA 2017
- Fundamental
- Price
- WINT $0.43
- NDRA $3.50
- Analyst Decision
- WINT Hold
- NDRA Strong Buy
- Analyst Count
- WINT 1
- NDRA 1
- Target Price
- WINT $350.00
- NDRA $46.00
- AVG Volume (30 Days)
- WINT 7.1M
- NDRA 32.0K
- Earning Date
- WINT 08-18-2025
- NDRA 08-13-2025
- Dividend Yield
- WINT N/A
- NDRA N/A
- EPS Growth
- WINT N/A
- NDRA N/A
- EPS
- WINT N/A
- NDRA N/A
- Revenue
- WINT N/A
- NDRA N/A
- Revenue This Year
- WINT N/A
- NDRA N/A
- Revenue Next Year
- WINT N/A
- NDRA N/A
- P/E Ratio
- WINT N/A
- NDRA N/A
- Revenue Growth
- WINT N/A
- NDRA N/A
- 52 Week Low
- WINT $0.36
- NDRA $2.90
- 52 Week High
- WINT $737.44
- NDRA $197.75
- Technical
- Relative Strength Index (RSI)
- WINT 35.91
- NDRA 51.99
- Support Level
- WINT $0.52
- NDRA $3.14
- Resistance Level
- WINT $0.64
- NDRA $3.60
- Average True Range (ATR)
- WINT 0.09
- NDRA 0.20
- MACD
- WINT -0.00
- NDRA 0.05
- Stochastic Oscillator
- WINT 14.12
- NDRA 72.13
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.